ESR1 and endometrial cancer: To evaluate the use of maintenance letrozole + abemaciclib vs. pembrolizumab after carboplatin + paclitaxel + pembrolizumab chemotherapy in participants with advanced or recurrent estrogen receptor-positive, mismatch repair proficient, TP53 wild-type endometrial cancer